|Over a week ago|
Largest borrow rate increases among liquid names » 08:4503/2403/24/20
GME, SIL, PSEC, TAK, CVNA, VAL, CHK, OPK, TVTY, SKT
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: GameStop (GME) 101.37% +19.88, Global X Silver Miners (SIL) 3.17% +0.92, Prospect Capital (PSEC) 10.38% +0.65, Takeda Pharmaceutical (TAK) 0.85% +0.60, Carvana (CVNA) 3.08% +0.52, Valaris Plc (VAL) 3.90% +0.44, Chesapeake (CHK) 28.86% +0.43, Opko Health (OPK) 1.41% +0.42, Tivity Health (TVTY) 1.66% +0.39, and Tanger Factory (SKT) 10.33% +0.38.
Tivity Health price target lowered to $4 from $18 at Craig-Hallum » 08:5803/1603/16/20
Craig-Hallum analyst Alex…
Craig-Hallum analyst Alex Fuhrman lowered the firm's price target on Tivity Health to $4 from $18 to reflect the cost of social distancing. The analyst keeps a Hold rating on the shares.
|Over a month ago|
Tivity Health announces agreement with HG Vora Capital to add new directors » 09:2702/2502/25/20
Tivity Health announced…
Tivity Health announced that its Board of Directors will appoint two new independent directors under an agreement with HG Vora Capital Management, a Tivity Health shareholder that owns approximately 9.9% of the company's outstanding shares. It is expected that HG Vora will name the new directors and they will join the Board in the next several weeks. They will be nominated for election at the company's 2020 Annual Meeting of Shareholders, replacing two current Board members who will not stand for reelection.
Fly Intel: Wall Street's top stories for Thursday » 17:1202/2002/20/20
MS, ETFC, GS, LB, DLGNF, IOTS, AMRC, ENGIY, VIAC, VIACA, SIX, PG, DPZ, STMP, CYH, TVTY, AAN
Stocks slid as Microsoft…
Fly Intel: Wall Street's top stories at midday » 12:2802/2002/20/20
MS, ETFC, LB, IOTS, DLGNF, VIAC, SIX, DPZ, STMP, CYH, TEVA, TVTY, AAN
Stocks are down at midday…
'Extremely disappointed' Barrington cuts Tivity Health target to $24 » 09:2902/2002/20/20
Barrington analyst Michael Petusky is "extremely disappointed" after Tivity Health reporter weaker than expected results and terminated its CEO. The Nutrition business is "still a mess," Petusky tells investors in a post-earnings research. Tivity shares "will almost without a doubt spend at least a couple of quarters in the penalty box," says the analyst. He lowered lowered his price target on Tivity to $24 from $38 but keeps an Outperform rating on the name.
Tivity Health downgraded to Hold from Buy at Craig-Hallum » 09:1902/2002/20/20
Craig-Hallum analyst Alex…
Craig-Hallum analyst Alex Fuhrman downgraded Tivity Health to Hold from Buy with a price target of $18, down from $30. The analyst cited lower than expected 2020 guidance. While he continues to believe that there is significant potential for synergies by leveraging Tivity Health's nutrition segment to sell into healthcare channels, this opportunity has been eclipsed for now by what will likely be a third consecutive year of revenue declines for Nutrition segment. Given significant turnover in the senior leadership and the fact that January and February represent the biggest recruitment months for Nutrisystem, Fuhrman believes it is unlikely that this segment will show meaningful improvement in 2020.
Jefferies sees too much uncertainty at Tivity Health, downgrades to Hold » 07:5702/2002/20/20
As previously reported,…
As previously reported, Jefferies analyst David Styblo downgraded Tivity Health to Hold from Buy with a price target of $16, down from $28, as revenue in the Nutrition business is now expected to decline 9% in 2020, versus his prior expectation for it to increase 7-8%, and Healthcare segment margins are expected to be down nearly 200 basis points this year versus a modest increase in his previous model. Additionally, the CEO and head of Nutrition have exited the company, leaving "too many uncertainties," said Styblo, who is among at least four Wall Street analysts who lowered their ratings on Tivity this morning.
Tivity Health downgraded to Hold from Buy at SunTrust » 07:2002/2002/20/20
SunTrust analyst David…
SunTrust analyst David MacDonald downgraded Tivity Health to Hold from Buy with a price target of $15, down from $25, after its Q4 earnings miss. The analyst cites the company's continued deterioration in the Nutrition business, margin pressure in Healthcare, management transitions and disappointing guidance, adding that while its fitness/nutrition business offers "conceptual attractiveness", its execution has been "elusive".
Cantor downgrades Tivity Health to Neutral, cuts target to $17 from $40 » 06:5602/2002/20/20
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Steven Halper downgraded Tivity Health to Neutral from Overweight with a price target of $17, down from $40. The company reported "disappointing" Q4 results and more importantly, its 2020 Nutrition segment guidance was well-below estimates, Halper tells investors in a research note. Given that Nutrition is a seasonal business, the analyst sees very few catalysts over the next nine months to drive the stock's valuation levels higher.